
|Articles|August 1, 2003
New overactive bladder drugs aim for less side effects
Chicago-Pharmacologic treatment of overactive bladder-once the private domain of only two or three agents-is about to expand significantly, providing urologists with a number of new therapeutic options.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Sildenafil cream for female sexual arousal disorder available to prescribe in select states
2
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
3
Experts urge FDA to revisit labeling for testosterone replacement therapy in men
4
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
5















